Abstract 2445
Background
To evaluate the clinicopathological factors and the oncology outcomes of invasive lobular carcinoma (ILC) patients compared with those of invasive ductal carcinoma (IDC) patients.
Methods
This study was a medical record review based on a prospectively-collected database. We surveyed the clinicopathological characteristics and oncology survival between IDC and ILC following curative surgery at ooo Medical Center between March 2007 and February 2015.
Results
The median follow-up time was 60.5 months (range: 3-121 months). There were 352 breast cancer patients with ILC and 7795 breast cancer patients with IDC. There were 13 breast cancer patients with ILC and 1150 breast cancer patients with IDC in the TNBC patients. The IDC patients had 77.7% of cytokeratin (CK) 5/6 and 86.3% of Epidermal growth factor receptor (EGFR), while ILC patients only had 15.4% of CK5/6 and 23.1% of EGFR. In TNBC, patients with ILC showed a tendency to have a worse prognosis than patients with IDC. However, there was no statistical difference in disease-free survival (DFS, p = 0.122) or overall survival (OS, p = 0.093) between TNBC patients with IDC and with ILC.
Conclusions
Patients with ILC have no different oncologic outcome than patients with IDC. However, patients with ILC in TNBC show a tendency to have a worse prognosis than patients with IDC in TNBC. This result may be related to CK5/6 and EGFR. Further research is needed with larger sample sizes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5873 - Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
Presenter: Donna Fitzgerald
Session: Poster Display session 2
Resources:
Abstract
3588 - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: a translational approach.
Presenter: Anna Adam-Artigues
Session: Poster Display session 2
Resources:
Abstract
5640 - Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
Presenter: Marija Balic
Session: Poster Display session 2
Resources:
Abstract
2616 - Clinical application of mutational analysis in breast cancer patients: the relevance of PIK3CA analysis for precision medicine.
Presenter: Juan Miguel Cejalvo
Session: Poster Display session 2
Resources:
Abstract
3870 - A retrospective gene expression analysis of surgically-removed Breast Cancer Brain Metastasis (BCBM)
Presenter: Meritxell Mallafré-Larrosa
Session: Poster Display session 2
Resources:
Abstract
1240 - Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: meta-analysis of Phase II and III randomized clinical trials
Presenter: Claudia Omarini
Session: Poster Display session 2
Resources:
Abstract
5535 - Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): management and time course of key adverse events of special interest (AESIs) in SOLAR-1
Presenter: Hope Rugo
Session: Poster Display session 2
Resources:
Abstract
3093 - Changes in Hormone-Receptor status in Luminal breast cancers between primary tumor and metastases: results of the observational cohort GIM-13 AMBRA Study
Presenter: Marina Cazzaniga
Session: Poster Display session 2
Resources:
Abstract
1378 - MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)
Presenter: Miguel Martín
Session: Poster Display session 2
Resources:
Abstract
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract